InvestorsHub Logo
Followers 30
Posts 5054
Boards Moderated 0
Alias Born 01/07/2020

Re: None

Monday, 08/03/2020 10:21:42 AM

Monday, August 03, 2020 10:21:42 AM

Post# of 425933
On behalf of Amarin and all shareholders I'm offended by this message:

First non-statin cholesterol drug bags FDA approval
This year also witnessed the first non-statin treatment to be cleared for sale in the US in nearly 20 years. The drug, bempedoic acid, is made by Esperion Therapeutics Inc. This cholesterol-lowering drug is aimed at helping millions of people who can’t tolerate or don’t get enough help from widely used statin pills like Lipitor and Crestor.

This new drug is to be used as an add-on treatment with statins. It lowers bad cholesterol or low-density lipoprotein (LDL) by inhibiting its synthesis in the liver. It targets patients with high cardiovascular risk.

Esperion also won approval of bempedoic acid in combination with ezetimibe, another cholesterol-lowering drug.

In January last year, Daiichi Sankyo Europe had entered into an exclusive licensing agreement with Esperion Therapeutics for Daiichi Sankyo Europe to market bempedoic acid and bempedoic acid/ezetimibe combination tablet in the European Economic Area and Switzerland.


Found on the site here below (New FDA approvals) scroll down the page until above text:

https://www.pharmacompass.com/radio-compass-blog/new-drug-approvals-by-fda-ema-mid-2020-recap?utm_source=pharmacompass

Jasbg

PS: somebody is being very here active here - never heard of this before. Anyone know what it is about ?

http://www.zclchemicals.com/?utm_source=pharmacompass
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News